進行がん（NRAS/KRAS遺伝子変異陽性）の様々な病型を有する日本人を対象に、BI 3011441の異なる投与量を試験する研究

基本情報

NCT ID

NCT04742556

ステータス

完了

試験のフェーズ

第1相

試験タイプ

介入

目標被験者数

15

治験依頼者名

Boehringer Ingelheim

概要

This study is open to Japanese adults with different types of advanced cancer that are positive for NRAS/KRAS mutations. This is a study in people for whom previous treatment was not successful or no standard treatment exists. The purpose of this study is to find the highest dose of BI 3011441 that Japanese people with advanced cancer can tolerate. BI 3011441 is a medicine that may turn off a signal by NRAS/KRAS that makes tumours grow. Participants take BI 3011441 as capsules once a day. Participants can stay in the study as long as they benefit from treatment and can tolerate it. The doctors collect information on any health problems of the participants.

対象疾患

介入

依頼者（Sponsor）

実施施設 (2)